2029, Food and Drug Administration, Leads and Pharma

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2029

Food and Drug Administration

Leads

Pharma

Scorpion inks deal with Pierre Fabre for next-gen EGFR inhibitors

Pharmaceutical Technology

APRIL 4, 2023

While Scorpion will lead the development of STX-721, Pierre Fabre will handle STX-241. The Boston, Massachusetts-based Scorpion expects to submit an investigational new drug (IND) application for STX-721 to the US Food and Drug Administration (FDA) in mid-2023, with an IND application for STX-241 expected in H1 2024.

Food and Drug Administration

Food and Drug Administration Biopharma FDA Pharmaceutical

Intercept receives orphan drug designation for liver disease combo therapy

Pharmaceutical Technology

MAY 17, 2023

The US Food and Drug Administration (FDA) has awarded an orphan drug designation to Intercept Pharmaceuticals’ fixed-dose combination of obeticholic acid and bezafibrate for the treatment of primary biliary cholangitis. This results in bile buildup in the liver and can lead to scarring. billion in 2029.

Food and Drug Administration

Food and Drug Administration FDA Pharmaceutical Prospecting

Pharma Rep Focus

Scorpion inks deal with Pierre Fabre for next-gen EGFR inhibitors

Intercept receives orphan drug designation for liver disease combo therapy

Stay Connected